Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma

International Journal of Hematology

Volumn 88, Issue 4, 2008, Pages 396-402

  Maruyama, Dai ^a   Watanabe, Takashi ^a   Heike, Yuji ^a   Nagase, Kumiko ^a   Takahashi, Noriko ^a   Yamasaki, Satoshi ^a   Waki, Fusako ^a   Yokoyama, Hiroki ^a   Kim, Sung Won ^a   Kobayashi, Yukio ^a   Aizawa, Shin ^b   Tobinai, Kensei ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

Bone marrow stromal cells; Bortezomib; IFN ; IL 6; Multiple myeloma; Pro inflammatory cytokine

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 6; MELPHALAN; NAVELBINE; PREDNISOLONE; RANIMUSTINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE; ANTINEOPLASTIC AGENT; AUTACOID; BORONIC ACID DERIVATIVE; CYTOKINE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY TEMPERATURE; BONE MARROW CELL; CANCER PATIENT; CELL FUNCTION; CELL LINEAGE; CLINICAL ARTICLE; CLINICAL TRIAL; COCULTURE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG FEVER; DRUG MEGADOSE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MACROPHAGE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; STROMA CELL; TREATMENT RESPONSE; BLOOD; CHEMICALLY INDUCED DISORDER; FEVER; MIDDLE AGED; SECRETION; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; BORONIC ACIDS; CELL LINE, TUMOR; CYTOKINES; FEMALE; FEVER; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; STROMAL CELLS;

EID: 64249112700     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0194-0     Document Type: Article

References (18)

1. T Hideshima P Richardson D Chauhan 2001 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 3071 6
2. T Hideshima D Chauhan P Richardson 2002 NF-kappa B as a therapeutic target in multiple myeloma J Biol Chem 277 16639 47
3. PG Richardson B Barlogie J Berenson 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 17
4. S Jagannath B Barlogie J Berenson 2004 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 165 72
5. P Richardson P Sonneveld MW Schuster 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487 98
6. S Jagannath BG Durie J Wolf 2005 Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 776 83
7. S Miyakoshi M Kami K Yuji 2006 Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma Blood 107 3492 4
8. A Gotoh K Ohyashiki K Oshimi 2006 Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology Int J Hematol 84 406 12
9. V Pitini C Arrigo G Altavilla C Naro 2007 Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis? Leuk Res 31 1027 8
10. RZ Orlowski TE Stinchcombe BS Mitchell 2002 Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies J Clin Oncol 20 4420 7
11. J Bladé D Samson D Reece 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation Br J Haematol 102 1115 23
12. S Aizawa M Yaguchi M Nakano S Inokuchi H Handa K Toyama 1991 Establishment of a variety of human bone marrow stromal cell lines by the recombinant SV40-adenovirus vector J Cell Physiol 148 245 51
13. S Aizawa M Yaguchi M Nakano 1994 Hematopoietic supportive function of human bone marrow stromal cell lines established by a recombinant SV40-adenovirus vector Exp Hematol 22 482 7
14. Geoffrey LU, Matthew SH, Nicholas MF, et al. Bortezomib alters peripheral blood lymphocyte subsets in patients with multiple myeloma. Blood 2005;106:2387a.
15. G Hess V Wagner A Kreft CP Heussel C Huber 2006 Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patients with multicentric Castleman Disease Br J Haematol 134 544 5
16. CK Min S Lee YJ Kim 2006 Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines Eur J Haematol 76 265 8
17. J Shen J Reis DC Morrison 2006 Key inflammatory signaling pathways are regulated by the proteasome Shock 25 472 84
18. V Costes M Portier Z-Y Lu JF Rossi R Bataille B Klein 1998 Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production Br J Haematol 103 1152 60